A rash or a reaction where you inject can occur with GLP-1 medicines. In adult weight-loss trials of Wegovy injection, 1.4% of treated patients and 1% of placebo patients had injection site reactions. That figure covers local reactions such as itching, redness and irritation [1].
What Wegovy trials and labeling report
Our GLP-1 side-effect guide puts local symptoms in context alongside common effects like nausea. A local reaction can include redness, itching, swelling or firm skin at the injection site. In the pediatric Wegovy injection weight-loss trial, rash and hives were each reported in 3% of treated patients and 0% of placebo patients [1].
If you develop a new rash without emergency symptoms, contact your prescriber for advice. Wegovy’s label lists a prior serious allergic reaction to semaglutide or any ingredient in Wegovy as a contraindication [1].
What FDA adverse event reports can show
Our guide to FDA adverse event reports explains how these reports help identify possible safety signals. In a 2018–2024 analysis of four GLP-1 medicines, skin-related events accounted for 8.16% of the semaglutide reports and 5.75% across the four medicines. The category included symptoms other than rash, such as itching and hair loss [2].
Skin events made up a smaller share of GLP-1 reports than of reports about DPP-4 inhibitors in that analysis (proportional reporting ratio 0.27, 95% confidence interval 0.257–0.284). Those are proportions among submitted reports. They cannot tell us how often patients experience these reactions or which medicine is safer for a particular person [2].
Clinicians have published individual cases of suspected hypersensitivity and fixed drug eruption after semaglutide use. These reports describe what can prompt evaluation, but cannot establish how often those reactions happen[3] [4].